# Alterations of Bioactive Lipid Profiles in the Retina Following Traumatic Optic Neuropathy in Mice

## TL;DR

This study investigates changes in bioactive lipid profiles in the retina of mice after traumatic optic neuropathy, finding trends in lipid metabolism that may inform future treatments.

## Contribution

The study provides new insights into lipid metabolism changes in TON using LC/MS analysis of retinal tissues.

## Key findings

- No individual lipid showed statistically significant differences after FDR correction.
- Trends showed increased expression of LOX- and CYP-derived metabolites from PUFA substrates.
- Findings suggest lipid-mediated inflammation as a potential therapeutic target in TON.

## Abstract

Traumatic optic neuropathy (TON) causes vision loss through compression and contusion, yet there is no consensus on the most effective treatment. Polyunsaturated fatty acid (PUFA)-derived bioactive lipids metabolized by lipoxygenase (LOX), cytochrome P450 (CYP), and cyclooxygenase (COX) enzymes are known mediators of inflammation and neurodegeneration. However, their role in TON-related retinal pathology remains unclear. Controlled orbital impact (COI) was used to induce unilateral TON in mice with controlled velocity (2–3 m/s), with the fellow eye serving as an internal control. Retina tissues were collected three days post-injury and analyzed by LC/MS to quantify bioactive lipid metabolites from ω−6 and ω−3 PUFAs. Statistical analysis was performed using paired, nonparametric Wilcoxon signed-rank tests with Benjamini–Hochberg false discovery rate (FDR) correction. Results showed that among 38 reliably detected metabolites, no individual lipid showed a statistically significant difference between TON and control eyes after FDR correction (q < 0.05). However, both individual and pathway-level analysis revealed consistent trends toward increased expression of LOX- and CYP-derived metabolites across FDA PUFA substrates, including arachidonic acid (AA), linoleic acid (LA), and docosahexaenoic acid (DHA). These findings support further investigation into lipid-mediated inflammation in TON and its potential as a therapeutic target, particularly through expanding both the sample size and the post-TON time periods.